TENIPOSIDE is an Oncology drug manufactured by WG Critical Care and administered via the Intravenous route of administration. The Q Code: Q2017 is aligned to the drug TENIPOSIDE.
TENIPOSIDE – Q2017
read more
Q Code
ACTEMRA – Q0249
ACTEMRA is a COVID-19 drug manufactured by Genentech and administered via the Intravenous route of administration. The Q Code: Q0249 is aligned to the drug ACTEMRA.
Sotrovimab Injection – Q0247
Sotrovimab Injection is a COVID-19 drug manufactured by GSK and administered via the Intravenous route of administration. The Q Code: Q0247 is aligned to the drug Sotrovimab Injection.
OGIVRI – Q5114
OGIVRI is an Oncology Biosimilar drug manufactured by Mylan and administered via the Intravenous route of administration. The Q Code: Q5114 is aligned to the drug OGIVRI.
Apligraf Disk – Q4101
Apligraf Disk is a Wound Care drug manufactured by Organogenesis and administered via the Topical application route of administration. The Q Code: Q4101 is aligned to the drug Apligraf Disk.
HERZUMA – Q5113
HERZUMA is an Oncology Biosimilar drug manufactured by Teva and administered via the Intravenous route of administration. The Q Code: Q5113 is aligned to the drug HERZUMA.
EPOGEN – Q4081
EPOGEN is an Oncology drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q4081 is aligned to the drug EPOGEN.
ONTRUZANT – Q5112
ONTRUZANT is an Oncology Biosimilar drug manufactured by Merck and administered via the Intravenous route of administration. The Q Code: Q5112 is aligned to the drug ONTRUZANT.
UDENYCA – Q5111
UDENYCA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Coherus Biosciences Inc and administered via the Subcutaneous route of administration. The Q Code: Q5111 is aligned to the drug UDENYCA.
NIVESTYM – Q5110
NIVESTYM is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Pfizer and administered via the Injection route of administration. The Q Code: Q5110 is aligned to the drug NIVESTYM.
FULPHILA – Q5108
FULPHILA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Mylan and administered via the Subcutaneous route of administration. The Q Code: Q5108 is aligned to the drug FULPHILA.
MVASI – Q5107
MVASI is an Oncology Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5107 is aligned to the drug MVASI.